7EYC
Crystal structure of Tau and acetylated tau peptide antigen
7EYC の概要
エントリーDOI | 10.2210/pdb7eyc/pdb |
分子名称 | antibody, light chain, antibody, Heavy chain, ACETYLATED TAU PEPTIDE, ... (4 entities in total) |
機能のキーワード | antibody, tau, alzheime disease, protein binding, immune system |
由来する生物種 | Mus musculus (Mouse) 詳細 |
タンパク質・核酸の鎖数 | 6 |
化学式量合計 | 95154.54 |
構造登録者 | |
主引用文献 | Song, H.L.,Kim, N.Y.,Park, J.,Kim, M.I.,Jeon, Y.N.,Lee, S.J.,Cho, K.,Shim, Y.L.,Lee, K.H.,Mun, Y.S.,Song, J.A.,Kim, M.S.,Pack, C.G.,Jung, M.,Jang, H.,Na, D.L.,Hong, M.,Kim, D.H.,Yoon, S.Y. Monoclonal antibody Y01 prevents tauopathy progression induced by lysine 280-acetylated tau in cell and mouse models. J.Clin.Invest., 133:-, 2023 Cited by PubMed Abstract: The spatiotemporal pattern of the spread of pathologically modified tau through brain regions in Alzheimer's disease (AD) can be explained by prion-like cell-to-cell seeding and propagation of misfolded tau aggregates. Hence, to develop targeted therapeutic antibodies, it is important to identify the seeding- and propagation-competent tau species. The hexapeptide 275VQIINK280 of tau is a critical region for tau aggregation, and K280 is acetylated in various tauopathies, including AD. However, the mechanism that links tau acetylated on lysine 280 (tau-acK280) to subsequent progression to neurodegenerative disease remains unclear. Here, we demonstrate that tau-acK280 is critical for tau propagation processes including secretion, aggregation, and seeding. We developed an antibody, Y01, that specifically targets tau-acK280 and solved the crystal structure of Y01 in complex with an acK280 peptide. The structure confirmed that Y01 directly recognizes acK280 and the surrounding residues. Strikingly, upon interaction with acetylated tau aggregates, Y01 prevented tauopathy progression and increased neuronal viability in neuron cultures and in tau-Tg mice through antibody-mediated neutralization and phagocytosis, respectively. Based on our observations that tau-acK280 is a core species involved in seeding and propagation activities, the Y01 antibody that specifically recognizes acK280 represents a promising therapeutic candidate for AD and other neurodegenerative diseases associated with tauopathy. PubMed: 36917188DOI: 10.1172/JCI156537 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.49 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
